Treatment of Rectal Adenocarcinoma

Risk Stratification and Treatment Selection

• The European Society for Medical Oncology recommends treatment decisions based on clinical staging using endorectal ultrasound for early tumors or rectal MRI for all others to assess depth of invasion, nodal status, and relationship to the mesorectal fascia 1, 2, 3
• For T1 sm1-2 tumors without vessel invasion or poor differentiation, the National Comprehensive Cancer Network suggests local excision using transanal endoscopic microsurgery (TEM) is appropriate 3, 4
• The American Joint Committee on Cancer recommends that the resection must be complete with safe margins (R0) and no signs of vessel invasion or poor differentiation 3
• If deeper submucosal invasion or T2 tumors are present, the recurrence risk exceeds 10% and immediate radical surgery with total mesorectal excision (TME) is required, as recommended by the European Society for Medical Oncology 3, 4

Intermediate/Locally Advanced Disease

• The National Comprehensive Cancer Network recommends preoperative therapy is strongly preferred over postoperative treatment because it is more effective and less toxic 1, 2, 3, 4
• The European Society for Medical Oncology suggests two preoperative approaches are acceptable: short-course radiotherapy or long-course chemoradiotherapy 3, 4

Surgical Approach

• The American College of Surgeons recommends total mesorectal excision (TME) with sharp dissection is mandatory for all rectal lesions not amenable to local excision 5, 6, 3
• The National Comprehensive Cancer Network suggests at least 12 lymph nodes should be examined pathologically 1, 2

Metastatic Disease

• The European Society for Medical Oncology recommends for patients with resectable liver or lung metastases, surgical resection should be considered as part of curative-intent treatment 1, 2, 7
• The National Comprehensive Cancer Network suggests first-line palliative chemotherapy should be initiated early and consists of 5-FU/leucovorin combined with either oxaliplatin or irinotecan, with or without bevacizumab 1, 2, 7

Recurrent Disease

• The American College of Radiology recommends patients with local recurrence who did not receive prior radiotherapy should receive preoperative radiotherapy with concurrent chemotherapy 1, 2, 7
• The National Comprehensive Cancer Network suggests surgery should be attempted 6-8 weeks after radiotherapy 1, 2

Total Mesorectal Excision for Rectal Cancer

Surgical Technique and Quality Requirements

• The European Society for Medical Oncology recommends that the quality of TME execution is the single most critical factor determining oncologic outcomes, with complete excision of the entire mesorectal envelope and sharp dissection along the avascular plane between the mesorectal fascia and presacral fascia 8, 9, 10
• The American Joint Committee on Cancer suggests achievement of negative circumferential resection margins (CRM), with tumor clearance >1mm from the mesorectal fascia being essential for oncologic adequacy 8

Technical Modifications by Tumor Location

• For upper rectal tumors, the National Comprehensive Cancer Network recommends partial mesorectal excision is acceptable with a mesorectal margin ≥5 cm distal to the tumor 8
• For low-lying rectal tumors requiring abdominoperineal excision, the European Society for Medical Oncology recommends critical technical modification required, with dissection from above stopping at the tip of the coccyx, then continuing from below to achieve a cylindrical specimen 8, 9, 11

Integration with Multimodal Therapy

• For early favorable disease (cT1-2, early cT3a-b, N0, clear mesorectal fascia), the National Comprehensive Cancer Network recommends TME alone without neoadjuvant therapy, as local recurrence risk is very low 8
• For intermediate risk disease (most cT3, N+, EMVI+), the European Society for Medical Oncology recommends preoperative radiotherapy followed by TME, reducing local recurrence 8, 9

Outcomes and Quality Assurance

• The American Society of Clinical Oncology states that TME performed with proper technique achieves local recurrence rates of 3-7% in curative resections 8
• The European Society for Medical Oncology recommends critical quality control measures, including surgeon and/or pathologist evaluation of mesorectal specimen quality (complete, nearly complete, or incomplete) 8
• The Society of Surgical Oncology suggests documentation that surgeons can be trained in TME technique with resultant reduction in local recurrence rates 9, 10, 11

Surgical Management of Low Rectal Cancer

Preoperative Treatment

• The European Society for Medical Oncology recommends preoperative radiotherapy with a dose of 25 Gy, 5 Gy/fraction over 1 week, followed by surgery within 10 days, for patients with mid/advanced-stage rectal cancer (cT3, cT4a, N+) 12, 13
• The American Society of Clinical Oncology suggests preoperative chemoradiotherapy with a dose of 45-50.4 Gy, 1.8-2 Gy/fraction, combined with 5-FU, for patients with locally advanced rectal cancer (cT3 mrf+, cT4) 12, 13, 14

Surgical Techniques

• The National Comprehensive Cancer Network recommends total mesorectal excision (TME) as the standard surgical technique for low rectal cancer, with the choice of technique depending on the exact location of the tumor relative to the anal verge and the degree of invasion 12, 13
• The European Society for Medical Oncology suggests that TME should be performed with a complete resection of the mesorectum, with a clear margin of at least 1mm from the mesorectal fascia, and with a minimum of 12 lymph nodes examined 12, 14

Postoperative Treatment

• The American Society of Clinical Oncology recommends postoperative chemoradiotherapy with a dose of 50 Gy, 1.8-2.0 Gy/fraction, with 5-FU, for patients with a positive circumferential margin, tumor perforation, or high risk of local recurrence if not previously irradiated 12, 15, 14
• The National Comprehensive Cancer Network suggests that adjuvant chemotherapy may be offered to patients with stage III (and high-risk stage II) rectal cancer, although the evidence is less robust than for colon cancer 15

Treatment of Rectal Adenocarcinoma

Neoadjuvant Therapy

• Preoperative chemoradiotherapy is strongly preferred over postoperative treatment due to superior efficacy and reduced toxicity, as recommended by the European Society for Medical Oncology 16, 17, 18
• Two acceptable neoadjuvant approaches exist: short-course radiotherapy (25 Gy in 5 fractions over 1 week) followed by immediate surgery within 10 days, or long-course chemoradiotherapy (50 Gy in 1.8-2.0 Gy fractions with concurrent 5-FU continuous infusion during weeks 1 and 5), followed by surgery 6-8 weeks later, according to the European Society for Medical Oncology 16, 17, 19, 18

Adjuvant Therapy

• Adjuvant chemotherapy (5-FU/leucovorin) may be offered postoperatively for stage III disease, though evidence is less robust than for colon cancer, as stated by the European Society for Medical Oncology 18

Palliative Therapy

• First-line palliative chemotherapy should be initiated early and consists of fluoropyrimidines (5-FU/leucovorin or capecitabine) combined with either oxaliplatin or irinotecan, with or without bevacizumab, as recommended by the European Society for Medical Oncology 19, 20, 18
• Second-line chemotherapy should be considered for patients with maintained good performance status, according to the European Society for Medical Oncology 16, 17, 19, 20, 18

Synchronous Oligo-Metastatic Disease

• If both primary tumor and metastases are resectable upfront: 5×5 Gy radiotherapy to primary followed by combination chemotherapy, then surgery for metastases and primary after 3 months, with pre- and postoperative chemotherapy totaling 6 months, as recommended by the European Society for Medical Oncology 19, 20

Critical Pitfalls to Avoid

• Never use postoperative chemoradiotherapy when preoperative treatment is feasible—it is more toxic and less effective, as stated by the European Society for Medical Oncology 16, 17, 18

Treatment of Locally Advanced Rectal Cancer

Neoadjuvant Chemoradiotherapy

• The National Comprehensive Cancer Network recommends preoperative chemoradiotherapy followed by total mesorectal excision surgery, then adjuvant chemotherapy, as the optimal treatment for locally advanced rectal cancer, with a radiation dose of 45-50.4 Gy delivered at 1.8-2.0 Gy per fraction over 5-6 weeks, and concurrent chemotherapy with 5-FU continuous infusion during weeks 1 and 5, or capecitabine 21
• The American Cancer Society suggests that preoperative therapy is mandatory and strongly preferred over postoperative treatment because it demonstrates superior efficacy with reduced toxicity, better tumor downstaging, improved sphincter preservation rates, and enhanced quality of life 21

Surgical Resection

• The European Society for Medical Oncology recommends that total mesorectal excision surgery is mandatory and represents the most critical determinant of oncologic outcomes, with complete excision of the entire mesorectal envelope with sharp dissection along the avascular plane between mesorectal fascia and presacral fascia, and negative circumferential resection margin with tumor clearance >1 mm from the mesorectal fascia 22
• The American Society of Colon and Rectal Surgeons suggests that laparoscopic or robotic-assisted TME should be considered after careful evaluation of the patient's medical history, performance status, and tumor characteristics 23, 24

Adjuvant Chemotherapy

• The National Comprehensive Cancer Network recommends adjuvant chemotherapy for stage III disease, with a standard regimen of 5-FU/leucovorin or FOLFOX, and a total duration of perioperative therapy not exceeding 6 months 21

Special Considerations

• The World Journal of Emergency Surgery suggests that for a woman in her late 50s who is fit with good performance status, standard-of-care therapy identical to younger patients should be pursued, with the goal of curative-intent treatment and prolongation of life as the primary objective 23, 24

TME Grading in Rectal Cancer

Definition and Grading System

• The quality of mesorectal excision is graded according to the plane of surgical dissection achieved, with a three-tier system consisting of complete, nearly complete, and incomplete grades 25, 26, 27
• A complete TME grade is characterized by an intact mesorectum with only minor irregularities of a smooth mesorectal surface, no defect deeper than 5 mm, no coning, and a smooth circumferential resection margin on slicing 25, 26
• A nearly complete TME grade is characterized by moderate bulk to mesorectum with irregularities of the mesorectal surface, moderate distal coning, and moderate irregularities of circumferential resection margin 25, 26
• An incomplete TME grade is characterized by little bulk to mesorectum with defects down onto muscularis propria and very irregular circumferential resection margin 25, 26

Assessment and Quality Control

• The specimen must be examined both as a whole (fresh) and as cross-sectional slices (fixed) to make adequate interpretation, with a smooth surface, without incisions, defects or cracks, as an indication of successful surgical excision of all mesorectal tissue 25, 26